The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs. (Q38916281)
Jump to navigation
Jump to search
scientific article
Language | Label | Description | Also known as |
---|---|---|---|
English | The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs. |
scientific article |
Statements
The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs (English)
Chiara Tarantelli
Ivo Kwee
Elena Bernasconi
Anastasios Stathis
Georg Stussi
Maurilio Ponzoni
Afua Adjeiwaa Mensah
Michela Boi
Monica Testoni
Esteban Cvitkovic
Eugenio Gaudio
Andrea Rinaldi
MarÃa Eugenia Riveiro
Patrice Herait
Giorgio Inghirami
26 January 2015